Can forest management based on natural disturbances maintain ecological resilience?

Given the increasingly global stresses on forests, many ecologists argue that managers must maintain ecological resilience: the capacity of ecosystems to absorb disturbances without undergoing fundamental change. In this review we ask: Can the emerging paradigm of natural-disturbance-based management (NDBM) maintain ecological resilience in managed forests? Applying resilience theory requires careful articulation of the ecosystem state under consideration, the disturbances and stresses that affect the persistence of possible alternative states, and the spatial and temporal scales of management relevance. Implementing NDBM while maintaining resilience means recognizing that (i) biodiversity is important for long-term ecosystem persistence, (ii) natural disturbances play a critical role as a generator of structural and compositional heterogeneity at multiple scales, and (iii) traditional management tends to produce forests more homogeneous than those disturbed naturally and increases the likelihood of unexpected catastrophic change by constraining variation of key environmental processes. NDBM may maintain resilience if silvicultural strategies retain the structures and processes that perpetuate desired states while reducing those that enhance resilience of undesirable states. Such strategies require an understanding of harvesting impacts on slow ecosystem processes, such as seed-bank or nutrient dynamics, which in the long term can lead to ecological surprises by altering the forest's capacity to reorganize after disturbance

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Quantification of the susceptibility of the native flora of the South-West Botanical Province, Western Australia, to Phytophthora cinnamomi

This study compares, for the first time, variation in estimates of susceptibility of native flora to Phytophthora cinnamomi Rands among four databases and proposes an estimate of the proportion of the flora of the South-West Botanical Province of Western Australia that is susceptible to the pathogen. Estimates of the susceptibility of south-western native flora to P. cinnamomi infection were obtained from databases for Banksia woodland of the Swan Coastal Plain, jarrah (Eucalyptus marginata Donn. ex Smith) forest, the Stirling Range National Park and Rare and Threatened Flora of Western Australia. For the woodland, forest and national park databases, hosts were naturally infected in uncontrolled diverse natural environments. In contrast, threatened flora were artificially inoculated in a shadehouse environment. Considerable variation occurred within taxonomic units, making occurrence within family and genus poor predictors of species susceptibility. Identification of intra-specific resistance suggests that P. cinnamomi could be having a strong selection pressure on some threatened flora at infested sites and the populations could shift to more resistant types. Similar estimates of the proportion of species susceptible to P. cinnamomi among the databases from the wide range of environments suggests that a realistic estimate of species susceptibility to P. cinnamomi infection in the south-western region has been obtained. The mean of 40% susceptible and 14% highly susceptible equates to 2284 and 800 species of the 5710 described plant species in the South-West Botanical Province susceptible and highly susceptible to P. cinnamomi, respectively. Such estimates are important for determining the cost of disease to conservation values and for prioritising disease importance and research priorities. P. cinnamomi in south-western Australia is an unparalleled example of an introduced pathogen with a wide host range causing immense irreversible damage to unique, diverse but mainly susceptible plant communities